News & Updates

Myeloma patients may benefit from mezigdomide-dexamethasone doublet
Myeloma patients may benefit from mezigdomide-dexamethasone doublet
08 Dec 2023 byAudrey Abella

In a study evaluating heavily pretreated patients with relapsed and refractory multiple myeloma (R/R MM), the combination of mezigdomide and dexamethasone showed promising preliminary efficacy, with myelosuppression and infection as primary toxicities.

Myeloma patients may benefit from mezigdomide-dexamethasone doublet
08 Dec 2023
Alanine tied to diabetes, BP, lipid profile but not CAD
Alanine tied to diabetes, BP, lipid profile but not CAD
07 Dec 2023

Plasma alanine or factors affecting alanine appear to contribute to an increased risk of diabetes, higher blood glucose, low-density lipoprotein cholesterol (LDL-C), and blood pressure (BP), but not coronary artery disease (CAD), reports a study.

Alanine tied to diabetes, BP, lipid profile but not CAD
07 Dec 2023